UK and boosts API capacity in Verona.

Aptuit increases API capacity to meet increased demand for integrated candidate-to-IND solutions Opens 1600L/1000L reactor stream at Oxford, UK and boosts API capacity in Verona, Italy Dr http://clomid25.com read more . Jonathan Goldman, CEO, Aptuit LLC, announced that Aptuit provides increased its global convenience of Active Pharmaceutical Component Manufacture because of elevated demand for API, and because of its integrated and extensive candidate-to-IND development option. Dr. Goldman stated, ‘Client demand for our top quality, integrated, fully inclusive candidate-to-IND solutions provides improved over 300 percent on an annual basis. As part of our strategy of buying our infrastructure, we consequently have opened a 1600L/1000L reactor stream at our renowned API service in Oxford internationally, UK and increased throughput at our 400L reactors at our world-class, integrated fully, former huge Pharma R&D middle of excellence in Verona, Italy.

clomid en ligne

today announced the pricing of an underwritten public offering of 7,150,000 shares of its common stock at a price of $7.30 per share. The web proceeds to ArQule from the sale of the shares, after deducting underwriting commissions and discount rates and estimated expenses, are anticipated to be approximately $48.7 million. The offering is expected to close on or around April 16, 2012, subject to customary closing conditions. Citigroup and Leerink Swann are acting as joint book-working managers for the providing. Lazard Capital Markets, RBC Capital Markets and Oppenheimer & Co. Are acting as co-managers. ArQule provides granted the underwriters a 30-time option to buy up to an additional 1,072,500 shares of common share. The expected net proceeds to ArQule referenced above usually do not include any net proceeds that ArQule would receive if the underwriters exercise such option to purchase additional shares..

Other Posts From "treatments":

Related Posts